Skip to main content

Table 1 Characteristics of patients with KRAS and BRAF wild-type metastatic colorectal cancer treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

  All patients (n = 62) FOLFOX + Cmab (n = 37) XELOX + Cmab (n = 25) P-value
No. women 28 (45.2 %) 18 (48.9 %) 10 (40.0 %) 0.502
Median (range) age (years) 66 (34–83) 67 (45–83) 66 (34–83) 0.769
ECOG performance status    0.885
 0 55 (88.7 %) 33 (89.2 %) 22 (88.0 %)  
 1 7 (11.3 %) 4 (10.8 %) 3 (12.0 %)  
Primary tumor site     0.193
 Colon 36 (58.1 %) 18 (48.6 %) 8 (32.0 %)  
 Rectum 26 (41.9 %) 19 (51.4 %) 17 (68.0 %)  
Metastatic site     
 Liver 47 (75.8 %) 29 (78.4 %) 18 (72.0 %) 0.136
 Lymph node 18 (29.0 %) 13 (35.1 %) 5 (20.0 %)  
 Lung 15 (24.2 %) 10 (27.0 %) 5 (20.0 %)  
 Other 8 (12.9 %) 2 (5.4 %) 6 (24.0 %)  
  1. Unless indicated otherwise, data show the number of patients in each group, with percentage in parentheses
  2. ECOG Eastern Cooperative Oncology Group